252 related articles for article (PubMed ID: 35116572)
1. A narrative review of combining radiation and immunotherapy in gastroesophageal cancers.
Yoon K; Chen YJ; Chao J
Transl Cancer Res; 2021 May; 10(5):2586-2595. PubMed ID: 35116572
[TBL] [Abstract][Full Text] [Related]
2. Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation.
Buchwald ZS; Wynne J; Nasti TH; Zhu S; Mourad WF; Yan W; Gupta S; Khleif SN; Khan MK
Front Oncol; 2018; 8():612. PubMed ID: 30619752
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses.
Chao J; He TF; D'Apuzzo M; Chen YJ; Frankel P; Tajon M; Chen H; Solomon S; Klempner SJ; Fakih M; Lee P
Adv Radiat Oncol; 2022; 7(1):100807. PubMed ID: 35071830
[TBL] [Abstract][Full Text] [Related]
4. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.
Dudzinski SO; Cameron BD; Wang J; Rathmell JC; Giorgio TD; Kirschner AN
J Immunother Cancer; 2019 Aug; 7(1):218. PubMed ID: 31412954
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Lee L; Matulonis U
Gynecol Oncol; 2019 Jul; 154(1):236-245. PubMed ID: 30995960
[TBL] [Abstract][Full Text] [Related]
7. Nanotechnology-enhanced radiotherapy and the abscopal effect: Current status and challenges of nanomaterial-based radio-immunotherapy.
Viswanath D; Park J; Misra R; Pizzuti VJ; Shin SH; Doh J; Won YY
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1924. PubMed ID: 37632203
[TBL] [Abstract][Full Text] [Related]
8. Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors.
Ma S; Chen F
Pathol Res Pract; 2022 Oct; 238():154110. PubMed ID: 36155325
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
[TBL] [Abstract][Full Text] [Related]
10. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
[TBL] [Abstract][Full Text] [Related]
11. Current clinical trials testing the combination of immunotherapy with radiotherapy.
Kang J; Demaria S; Formenti S
J Immunother Cancer; 2016; 4():51. PubMed ID: 27660705
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies.
Ukleja J; Kusaka E; Miyamoto DT
Front Oncol; 2021; 11():663852. PubMed ID: 34041029
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives.
Sewastjanow-Silva M; Yamashita K; Rosa Vicentini E; Hirschmann M; Pool Pizzi M; Trail AM; Waters RE; Rogers JE; Ajani JA
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1177-1181. PubMed ID: 36266061
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies.
Chen M; Li C; Sun M; Li Y; Sun X
Front Immunol; 2022; 13():1043517. PubMed ID: 36505480
[TBL] [Abstract][Full Text] [Related]
15. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
[TBL] [Abstract][Full Text] [Related]
16. Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations.
Johnsrud AJ; Jenkins SV; Jamshidi-Parsian A; Quick CM; Galhardo EP; Dings RPM; Vang KB; Narayanasamy G; Makhoul I; Griffin RJ
Radiat Res; 2020 Dec; 194(6):688-697. PubMed ID: 33348372
[TBL] [Abstract][Full Text] [Related]
17. Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies.
Solanki AA; Bossi A; Efstathiou JA; Lock D; Mondini M; Ramapriyan R; Welsh J; Kang J
Eur Urol Oncol; 2019 Feb; 2(1):79-87. PubMed ID: 30929848
[TBL] [Abstract][Full Text] [Related]
18. Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect.
Theelen WS; de Jong MC; Baas P
Lung Cancer; 2020 Apr; 142():106-113. PubMed ID: 32126451
[TBL] [Abstract][Full Text] [Related]
19. PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Tuyaerts S; Van Nuffel AMT; Naert E; Van Dam PA; Vuylsteke P; De Caluwé A; Aspeslagh S; Dirix P; Lippens L; De Jaeghere E; Amant F; Vandecasteele K; Denys H
BMC Cancer; 2019 May; 19(1):506. PubMed ID: 31138229
[TBL] [Abstract][Full Text] [Related]
20. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
